Cannabis and weight loss
Browse the latest research linking medical marijuana / medicinal cannabis and weight loss.

See also: obesity 
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
WIN55,AM6545 weight loss,obesity in mice via experiment Cannabinoid CB1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity Mar 2019
Action Pathway: CB1
Collectively, these results provide evidence that hyperphagia associated with DIO is driven by a mechanism that includes CB1R-mediated inhibition of gut-brain satiation signaling.
CBD weight loss, appetite supress Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Sept 2012
Furthermore, cannabidiol reduced food intake in line with some existing reports, supporting the need for further mechanistic and behavioral work examining possible anti-obesity effects of cannabidiol.
Rimonabant weight loss in humans via placebo trial (n=3045) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Mar 2006
Ingestion Method: 20mg/day
Neutral  In this multicenter trial, treatment with 20 mg/d of rimonabant plus diet for 2 years promoted modest but sustained reductions in weight and waist circumference and favorable changes in cardiometabolic risk factors. However, the trial was limited by a high drop-out rate and longer-term effects of the drug require further study.
Rimonabant weight loss in humans via placebo trial Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Apr 2005
Ingestion Method: 5, 25mg/day
CB1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 year, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors.
Rimonabant weight loss,diabetes in humans via placebo trial (n=1047) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Nov 2006
Ingestion Method: 5, 25mg/day
Positive  These data indicate that 20 mg/day rimonabant, in combination with diet and exercise, can produce a clinically meaningful reduction in bodyweight and improve HbA1c and a number of cardiovascular and metabolic risk factors in overweight or obese patients with type 2 diabetes inadequately controlled by metformin or sulphonylureas.
Rimonabant weight loss in humans via placebo trial (n=1036) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. Nov 2005
Positive  Selective CB1-receptor blockade with rimonabant significantly reduces body weight and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.
Rimonabant weight loss in humans via placebo trial (n=839) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. Apr 2008
Negative  After 18 months of treatment, the study failed to show an effect for rimonabant on disease progression for the primary end point (PAV) but showed a favorable effect on the secondary end point (TAV).
CBD obesity,weight loss in rats via experiment Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents Jun 2019
Ingestion Method: 10, 20, and 40 mg/kg, ip
Action Pathway: CB1,CB2
Taken together, the present findings suggest that CBD may have therapeutic potential in reducing binge eating and the development of obesity.